Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy

Bibliographic Details
Main Authors:	Shalin Rawal, Kamal Sharma, Aditya Shah, Shriya Bavishi, Cleris Christian, Parjanya Bhatt, Ashwati Konat
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-06-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	cost-effectiveness rivaroxaban dual pathway inhibitor incremental cost-effectiveness ratio (ICER) Quality-Adjusted Life-Years (QALY)
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.916705/full

Internet